CAR-T cells in the treatment of neurological autoimmune diseases

Chimeric antigen receptor T cells (CAR-T cells) have revolutionised cancer treatment by offering personalised therapy of unprecedented efficacy to patients with relapsed B-cell malignancies and myeloma. CAR-T cells are designed selectively to target CD19 or other B-cell antigens with high affinity, leading to a potent immune response and effective killing of malignant B cells. More recently, CAR-T treatment has been shown to be safe and effective in a very limited number of patients with severe, refractory autoimmune conditions such as systemic lupus erythematosus, systemic sclerosis and myositis. This paper describes the early use and feasibility of CAR-T therapies in the treatment of refractory autoimmune neurological diseases.

Authors

Institutions

Publication Details

Journal
Practical Neurology
Published
2026-01-06
DOI
https://doi.org/10.1136/pn-2025-004890
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

CAR-T cells in the treatment of neurological autoimmune diseases

Jeremy Rees, N. Davies, Jeremias Motte, Deanna Joe et al.
Practical Neurology
CAR-T cell therapy research
article

CAR-T cells in the treatment of neurological autoimmune diseases

Jeremy Rees, N. Davies, Jeremias Motte, Deanna Joe, Gerald T. Finnerty, S Keddie, Frederick W. Vonberg, Benjamin E. Schroeder, R H Gold, Nikos Gorgoraptis, Amy Edwards, Bo Sun, Ryan Keh, A. Carr, Mohammad Ashraghi, Mark A. Willis, Maria Isabel Leite
article en

Abstract

Chimeric antigen receptor T cells (CAR-T cells) have revolutionised cancer treatment by offering personalised therapy of unprecedented efficacy to patients with relapsed B-cell malignancies and myeloma. CAR-T cells are designed selectively to target CD19 or other B-cell antigens with high affinity, leading to a potent immune response and effective killing of malignant B cells. More recently, CAR-T treatment has been shown to be safe and effective in a very limited number of patients with severe, refractory autoimmune conditions such as systemic lupus erythematosus, systemic sclerosis and myositis. This paper describes the early use and feasibility of CAR-T therapies in the treatment of refractory autoimmune neurological diseases.

Practical Neurology
University Hospital of Wales (GB), Royal London Hospital (GB), University of Oxford (GB), King's College Hospital NHS Foundation Trust (GB), Salford Royal Hospital (GB), Chelsea and Westminster Hospital (GB), St. Josef-Hospital (DE), Oxford University Hospitals NHS Trust (GB), National Hospital for Neurology and Neurosurgery (GB), University College London (GB), Cardiff University (GB), Ruhr University Bochum (DE), University of Wales (GB)
Good health and well-being
Openalex Percentile: Top 96%
CAR-T cell therapy research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.